NPT1220-478
/ EVER Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 10, 2022
NPT1220-478, a small molecule inhibitor of TLR2 and TLR9 improves disease-relevant endpoints in the SOD1-G93A transgenic mouse model of amyotrophic lateral sclerosis
(Neuroscience 2022)
- "These studies with NPT1220-478 in the SOD1-G93A transgenic mouse line provide further rationale for targeting TLR2 & TLR9 as a disease modifying approach for ALS."
IO biomarker • Preclinical • Amyotrophic Lateral Sclerosis • CNS Disorders • TLR2 • TLR9
1 to 1
Of
1
Go to page
1